Allakos Inc (ALLK) - Total Assets
Based on the latest financial reports, Allakos Inc (ALLK) holds total assets worth $59.55 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Allakos Inc - Total Assets Trend (2016–2024)
This chart illustrates how Allakos Inc's total assets have evolved over time, based on quarterly financial data. Also see market value of Allakos Inc for the company's overall valuation and market capitalisation.
Allakos Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Allakos Inc's total assets of $59.55 Million consist of 88.6% current assets and 11.4% non-current assets. Review Allakos Inc (ALLK) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Allakos Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Allakos Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Allakos Inc's current assets represent 88.6% of total assets in 2024, a decrease from 95.7% in 2016.
- Cash Position: Cash and equivalents constituted 18.4% of total assets in 2024, down from 94.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Allakos Inc Competitors by Total Assets
Key competitors of Allakos Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Allakos Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.23 | 4.11 | 23.41 |
| Quick Ratio | 14.23 | 4.11 | 23.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $54.01 Million | $111.71 Million | $438.70 Million |
Allakos Inc - Advanced Valuation Insights
This section examines the relationship between Allakos Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.54 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | -60.3% |
| Total Assets | $96.60 Million |
| Market Capitalization | $29.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Allakos Inc's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Allakos Inc's assets decreased by 60.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Allakos Inc (2016–2024)
The table below shows the annual total assets of Allakos Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $96.60 Million | -60.35% |
| 2023-12-31 | $243.61 Million | -36.96% |
| 2022-12-31 | $386.42 Million | -27.75% |
| 2021-12-31 | $534.82 Million | -25.68% |
| 2020-12-31 | $719.62 Million | +39.22% |
| 2019-12-31 | $516.89 Million | +170.26% |
| 2018-12-31 | $191.26 Million | +119.76% |
| 2017-12-31 | $87.03 Million | +513.92% |
| 2016-12-31 | $14.18 Million | -- |
About Allakos Inc
As of May 15, 2025, operates as a subsidiary of Concentra Biosciences, LLC.